Tokenless

Scientific research

He Raised $70M to Cure Every Disease With AI

He Raised $70M to Cure Every Disease With AI

Samuel Rodriques, founder of Edison Scientific, shares his journey from physics to building an AI scientist named Kosmos. He discusses how AI agents are already making novel discoveries, including a potential cure for blindness, and are poised to revolutionize drug discovery. The conversation dives into AI's strengths in high-throughput reasoning, the critical bottlenecks in clinical trials, proposed reforms for the US medical system, and whether human scientists will still be needed in an age of hyper-intelligent AI.

How AI Is Accelerating Scientific Discovery Today and What's Ahead — the OpenAI Podcast Ep. 10

How AI Is Accelerating Scientific Discovery Today and What's Ahead — the OpenAI Podcast Ep. 10

Head of OpenAI for Science Kevin Weil and research scientist Alex Lupsasca discuss how frontier models like GPT-5 are beginning to accelerate scientific discovery. They cover real-world examples in physics, the evolving nature of human-AI collaboration in research, and the future trajectory of science in a new, AI-powered era.

No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara

No Priors Ep. 140 | With Benchling Co-Founder and CEO Sajith Wickramasekara

Sajith Wickramasekara, CEO of Benchling, discusses the broken economics of drug development, where high costs and failure rates stifle innovation. He explains how the biotech industry is facing a 'dot com' bust and new competition from China, and argues that AI agents and simulation can provide the solution by making science less artisanal and helping scientists create better molecules through faster, cheaper experiments.

America's Autism Crisis and How AI Can Fix Science with NIH Director Jay Bhattacharya

America's Autism Crisis and How AI Can Fix Science with NIH Director Jay Bhattacharya

Dr. Jay Bhattacharya, Director of the NIH, discusses his vision for reforming the institution by adopting a Silicon Valley-style portfolio approach to funding, tackling the replication crisis, supporting early-career scientists, and leveraging AI to accelerate biomedical research while rebuilding public trust in science.